97 active not recruiting. 97 Phase 2, 31 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 97 | Active not recruiting 97 |
| Phase 1 | 31 | Active not recruiting 31 |
| Phase 3 | 2 | Active not recruiting 2 |
Follow Nervous System Neoplasms: new trials by email Literature Review of Nervous System Neoplasms trials Research Report on Nervous System Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 2 Study to Evaluate Povetacicept in Adults With Generalized Myasthenia Gravis Povetacicept, Placebo - Myasthenia Gravis, Generalized | Phase 2 | Active not recruiting | Vertex Pharmaceuticals Incorporated | 34 | 2026-05-13 | 2026-10-29 |
| Study to Assess Safety, Efficacy, and Cellular Kinetics of YTB323 in Generalized Myasthenia Gravis YTB323 - Generalized Myasthenia Gravis | Phase 1 / Phase 2 | Active not recruiting | Novartis Pharmaceuticals | 15 | 2025-04-22 | 2026-09-04 |
| Intrathecal Dual Checkpoint Inhibitor (PD-1 and CTLA-4) in Combination With Pemetrexed for Leptomeningeal Metastasis QL1706 (bispecific antibody targeting PD-1 and CLTA-4), Pemetrexed (Alimta) - Leptomeningeal Metastasis, Pemetrexed | Phase 1 / Phase 2 | Active not recruiting | Guangzhou Medical University | 39 | 2025-03-17 | 2026-10-13 |
| RNA Lipid Particles Targeting Pediatric Recurrent Intracranial Malignancies and Other systEmic Solid Tumors pp65 RNA LP (DP1), pp65/tumor mRNA RNA-LP (DP2), Surgical Biopsy/Resection - Recurrent Pulmonary Osteosarcoma, Recurrent High-grade Glioma | Phase 1 / Phase 2 | Active not recruiting | University of Florida | 36 | 2025-03-12 | 2026-11-02 |
| Intrathecal Combination of Programmed Death-1 (PD-1)/Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Bispecific Antibody and Pemetrexed for Leptomeningeal Metastasis Cadonilimab (AK104), Pemetrexed (Alimta) - Leptomeningeal Metastasis | Phase 1 / Phase 2 | Active not recruiting | Guangzhou Medical University | 39 | 2025-03-07 | 2026-10-13 |
| A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer Cobolimab, Dostarlimab - Melanoma, Hodgkin Lymphoma | Phase 1 / Phase 2 | Active not recruiting | GlaxoSmithKline | 83 | 2025-03-06 | 2025-11-12 |
| Efficacy and Safety of Phentermine/Topiramate in Youth With Hypothalamic Obesity Phentermine / Topiramate Extended Release Oral Capsule [Qsymia], Placebo - Hypothalamic Obesity, Hypothalamic Tumor | Phase 2 | Active not recruiting | Seattle Children's Hospital | 24 | 2025-03-01 | 2026-10-16 |
| Phase 2b Imaging Study of RAD101 in Participants With Suspected Recurrent Brain Metastases RAD101 (18F-FPIA) - Brain Metastases From Solid Tumors | Phase 2 | Active not recruiting | Radiopharm Theranostics, Ltd | 30 | 2024-12-13 | 2026-08-12 |
| A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following Radiotherapy Abemaciclib, Temozolomide - Glioma | Phase 2 | Active not recruiting | Eli Lilly and Company | 45 | 2024-10-25 | 2026-07-17 |
| Evaluation of the Efficacy and Safety of Befotertinib Combined With Bevacizumab as First-Line Treatment for EGFR-Positive Non-Small Cell Lung Cancer With Brain Metastases: A Single-Arm, Open-Label, Prospective Phase II Clinical Study The treatment regimen is Befotertinib combined with Bevacizumab. - Non-small Cell Lung Cancer (NSCLC), EGFR Mutation-Positive Lung Cancer | Phase 2 | Active not recruiting | Li-kun Chen | 70 | 2024-09-04 | 2026-10-21 |
| Agnostic Therapy in Rare Solid Tumors Nivolumab - Urachal Cancer, Parathyroid Carcinoma | Phase 2 | Active not recruiting | Instituto do Cancer do Estado de São Paulo | 28 | 2024-07-16 | 2026-10-13 |
| Immune Checkpoint Inhibitor Combined With Pemetrexed Intrathecal Injection for Leptomeningeal Metastasis From Solid Tumors Toripalimab, pemetrexed - Leptomeningeal Metastasis | Phase 1 / Phase 2 | Active not recruiting | Guangzhou Medical University | 45 | 2024-06-30 | 2026-10-20 |
| T-DXd Therapy for HER2-low Breast Cancer Patients With Brain Metastases Trastuzumab-Deruxtecan (T-DXd) - Breast Cancer, Metastatic Breast Cancer | Phase 2 | Active not recruiting | MedSIR | 28 | 2024-06-05 | 2026-05-08 |
| Remote Cognitive Assessment and Wearable Device While Assessing the Impact of Metformin in Patients With History of Cranial Radiation Therapy Best Practice, Medical Device Usage and Evaluation, Metformin - Malignant Brain Neoplasm | Phase 2 | Active not recruiting | Mayo Clinic | 100 | 2024-05-31 | 2026-10-02 |
| Evaluate the Safety, Tolerability, Pharmacodynamics and Efficacy of CNP-106 in Subjects With Myasthenia Gravis CNP-106, Placebo - Myasthenia Gravis, Generalized Myasthenia | Phase 1 / Phase 2 | Active not recruiting | COUR Pharmaceutical Development Company, Inc. | 54 | 2024-05-30 | 2026-06-09 |
| A Phase 2 Study to Evaluate DNTH103 in Adults With Generalized Myasthenia Gravis (MAGIC) Claseprubart, Placebo - Myasthenia Gravis, Generalized | Phase 2 | Active not recruiting | Dianthus Therapeutics | 65 | 2024-02-23 | 2026-07-27 |
| A Phase 1b / 2 Drug Resistant Immunotherapy With Activated, Gene Modified Allogeneic or Autologous γδ T Cells (DeltEx) in Combination With Maintenance Temozolomide in Subjects With Recurrent or Newly Diagnosed Glioblastoma Autologous genetically modified gamma-delta T cells, Allogeneic genetically modified gamma-delta T cells - Glioblastoma | Phase 1 / Phase 2 | Active not recruiting | In8bio Inc. | 4 | 2023-09-08 | 2025-05-01 |
| SRS for NSCLC With Oligo-residual Intracranial Disease After First-line 3rd Generation EGFR-TKI EGFR-TK Inhibitor, Stereotactic radiotherapy - Brain Metastases, Non-small Cell Lung Cancer | Phase 2 | Active not recruiting | Fudan University | 202 | 2023-08-10 | 2025-09-15 |
| Secondary BRain Metastases Prevention After Isolated Intracranial Progression on Trastuzumab/Pertuzumab or T-DM1 in Patients With aDvanced Human Epidermal Growth Factor Receptor 2+ brEast Cancer With the Addition of Tucatinib Trastuzumab, Trastuzumab Emtansine (T-DM1), Pertuzumab - Brain Metastases, Human Epidermal Growth Factor 2 Positive Carcinoma of Breast | Phase 2 | Active not recruiting | Carey Anders, M.D. | 48 | 2023-03-23 | 2026-06-23 |
| ARISTOCRAT: Blinded Trial of Temozolomide +/- Cannabinoids Nabiximols, Temozolomide, Nabiximols-matched placebo - Glioblastoma, Brain Tumor | Phase 2 | Active not recruiting | University of Birmingham | 122 | 2023-02-03 | 2026-10-16 |
Showing 20 of 97. Sign in to see all of them.
Brain Neoplasms (52) · Central Nervous System Neoplasms (15) · Carcinoma, Non-Small-Cell Lung (11) · Glioma (11) · Medulloblastoma (11) · Melanoma (10) · Sarcoma (10) · Glioblastoma (9) · Breast Neoplasms (8) · Ependymoma (8) · Meningioma (8) · Hepatoblastoma (7) · Lung Neoplasms (7) · Myasthenia Gravis (7) · Neuroblastoma (7)
Nervous System Diseases (97) · Neoplasms (92) · Neoplasms by Site (89) · Central Nervous System Neoplasms (65) · Brain Diseases (58) · Central Nervous System Diseases (58) · Neoplasms by Histologic Type (57) · Neoplasms, Nerve Tissue (53) · Neuroectodermal Tumors (41) · Neoplasms, Germ Cell and Embryonal (40) · Neoplasms, Glandular and Epithelial (31) · Neoplasms, Neuroepithelial (25) · Respiratory Tract Diseases (18) · Skin Diseases (17)
Radiosurgery (11) · Nivolumab (8) · Magnetic Resonance Spectroscopy (7) · Specimen Handling (7) · Cyclophosphamide (6) · Ipilimumab (6) · Temozolomide (6) · pembrolizumab (6) · Bevacizumab (5) · Biopsy (5) · Carboplatin (5) · Cisplatin (5) · Pemetrexed (5) · Radiotherapy (5) · X-Rays (5)
National Cancer Institute (NCI) (10) · M.D. Anderson Cancer Center (7) · Massachusetts General Hospital (5) · Hoffmann-La Roche (4) · St. Jude Children's Research Hospital (4) · Eli Lilly and Company (3) · Guangzhou Medical University (3) · Memorial Sloan Kettering Cancer Center (3) · British Columbia Cancer Agency (2) · Dana-Farber Cancer Institute (2) · Fudan University (2) · H. Lee Moffitt Cancer Center and Research Institute (2) · InSightec (2) · University of Florida (2) · Alliance for Clinical Trials in Oncology (1)
United States (76) · Canada (17) · France (16) · Spain (16) · Australia (14) · Italy (13) · United Kingdom (13) · China (10) · Germany (9) · Denmark (7) · Poland (6) · Japan (5) · Netherlands (5) · South Korea (5) · Belgium (4)
Jing Li (3) · Amar Gajjar, MD (2) · Brigitte C Widemann, M.D. (2) · Hussein A Tawbi (2) · Nancy Wang, MD, MPH (2) · Priscilla Brastianos, MD (2) · Abi Vainstein-Haras, MD (1) · Alan Nichol, MD (1) · Alice Lee (1) · Andrew J Brenner (1) · Anwen Liu (1) · Asim Bag, MD (1) · Bing Lu (1)
PMID 31401903, PMID 31838007, PMID 40086048, PMID 21632855, PMID 28029918, PMID 29118225, PMID 29602646, PMID 29778738, PMID 31838015, PMID 31881853, PMID 31969335, PMID 32187457, PMID 32479604, PMID 32483359, PMID 32846060, PMID 32846061, PMID 33067126, PMID 33362722, PMID 33502920, PMID 33536190, PMID 33591402, PMID 33607632, PMID 33646820, PMID 33823018, PMID 33882143, PMID 33945291, PMID 34021033, PMID 34088726, PMID 34380663, PMID 34427452, PMID 34486544, PMID 34716198, PMID 34924145, PMID 35007270, PMID 35229827, PMID 35289329, PMID 35353553, PMID 35395680, PMID 35467749, PMID 35728046, PMID 35930972, PMID 36108661, PMID 36122315, PMID 36657661, PMID 36924196, PMID 37115514, PMID 37132182, PMID 37265412, PMID 37268724, PMID 37353270
U10CA180886 (6), 2023 (5), 2019 (3), U10CA180888 (2), UM1CA186689 (2), 2015 (1), 2017 (1), 2018 (1), 2025 (1), R01CA154619 (1), R01CA187076 (1), R01CA187079 (1), R01CA201130 (1), R01CA229646 (1), R01NS052274 (1)